In a heavily pretreated multiple myeloma (MM) population, daratumumab monotherapy at 16 mg/kg showed meaningful, durable, single-agent activity, with deep responses and a favorable safety profile, according to a new phase II study.
In a heavily pretreated multiple myeloma (MM) population, daratumumab monotherapy at 16 mg/kg showed meaningful, durable, single-agent activity, with deep responses and a favorable safety profile, according to a new phase II study presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29-June 2, 2015 in Chicago.1
Sagar Lonial, MD, who is with the Winship Cancer Institute at Emory University School of Medicine in Atlanta, and colleagues conducted a two-part, open-label, international, multicenter study. In part one, researchers determined the most effective dose in 34 patients. In part two, 90 additional patients were enrolled in the 16 mg/kg dosing group. The primary endpoint was overall response rate (ORR).
Daratumumab is a human anti-CD38 IgG1κ mAb. It has single-agent activity and it was tested in MM patients with ≥ 3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or double refractory to a PI and ImiD. The researchers reported on 106 patients who received 16 mg/kg of daratumumab. The cohort had a median time since diagnosis of 4.8 years. These patients had previously not responded to multiple therapies (96%; last PI and IMiD, 95%; pomalidomide, 63%: carfilzomib, 48%; alkylating agents, 78%).
The researchers found that the most common adverse events (≥ 20%) were fatigue (39.6%), anemia (33.0%), nausea (29.2%), thrombocytopenia (25.5%), back pain (22.6%), neutropenia (22.6%), and cough (20.8%). The researchers reported that infusion-related reactions (IRR, 42.5%) were mainly grade 1/2 during the first infusion, and no patients withdrew from the trial due to IRRs.
The investigators were pleased to see an ORR of 29.2%, with three complete responders and a high percentage of partial responders. The median duration of response was 7.4 months and the ORR was consistent across clinically relevant subgroups. The study demonstrated a median time to progression was 3.7 months. At the time of the presentation (June 1, 2015), the median overall survival (OS) had not been reached; however, the estimated 1-year OS rate was 65%.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment
July 6th 2020The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.